AEGiS-15IAC: Characteristics and initial virologic and Immunologic data from the CLARE (CORE Center Lopinavir/r Anti-retroviral Effectiveness)Cohort.

15th International AIDS Conference


Bangkok, Thailand - July 11-16, 2004

DonateNow
Print this article

Characteristics and initial virologic and Immunologic data from the CLARE (CORE Center Lopinavir/r Anti-retroviral Effectiveness)Cohort.

Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. B10238)

Sherer R, Adeyemi OM, Simeone E, Despotes J, Tschampa J
CORE Center, Cook County Hospital, Chicago, United States

BACKGROUND: To describe the efficacy, durability and tolerability of Lopinavir/r (LPV/r) based HAART regimens in an urban clinic population.

METHODS: A retrospective-prospective observational study. Between Oct 2002 and Oct 2003, HIV+ patients currently receiving LPV/r were enrolled in this study. Baseline information collected included demographics, Hepatitis B/C sero-status, antiretroviral history, baseline and nadir CD4. At each study visit, data on LFTs, CD4, VL, lipids, ARV changes were collected, and waist/hip measurements were performed. Initial data on the first 12 weeks of study follow up are presented.

RESULTS: 120 HIV+ pts who had received LPV/r for a median duration of 6 months (0-41 months) were enrolled. The mean age was 44 years, 77% were male, 74% AA, 17% Caucasian and 8% Hispanic. At baseline (initiation of LPV/r) 18 pts (15%) were ARV naïve, 66 pts (55%) had prior NNRTI experience; 79 pts (66%) had prior PI; 51pts (43%) had prior 3 class experience. In addition to LPV/r, 105 pts (91%) received NRTI's, 37pts (32%) NNRTI's and 15 (13%) a 2nd PI. At baseline the median CD4 and HIV RNA of the cohort were 177/mm3 and 4.34 log10copies/ml. CD4 and HIV RNA changes shown in the table (all values median).

CONCLUSIONS: In this diverse study population in a "real world" setting, there was a sustained immunologic and virologic response to LPV/r based regimens with the greatest benefits in treatment naïve patients. [table: see text]

Keywords: AEGIS, Pyrimidinones, Antiretroviral Therapy, Highly Active, HIV Protease Inhibitors, Anti-HIV Agents, HIV Infections, Acquired Immunodeficiency Syndrome, HIV-1, Virion, Retroviridae, HIV, HIV Seropositivity, Retrospective Studies, lopinavir, Male, Humans, virology, immunology

040711
B10238

Copyright © 2004 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.